Real-world experience of the 6 weekly schedule (q6w) of pembrolizumab in patients (pts) with metastatic non-small cell lung cancer (mNSCLC)

被引：0
|
作者：
Tariq, Noor-Ul-Ain [1 ]
Anderson, Christian [2 ]
Gartside, Eleanor [1 ]
Wong, Helen [1 ]
Dobson, Lisa [1 ]
Anthonypillai, Marry [1 ]
Griffiths, Richard [1 ]
Pope, Anthony [1 ]
机构：
[1] Clatterbridge Canc Ctr, Liverpool, Merseyside, England
[2] Univ Liverpool, Clatterbridge, England
来源：
LUNG CANCER | 2022年 / 165卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
80
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 50 条
  • [21] Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?
    Sacher, Adrian G.
    Le, Lisa W.
    Lau, Anthea
    Earle, Craig C.
    Leighl, Natasha B.
    CANCER, 2015, 121 (15) : 2562 - 2569
  • [22] Correlation between depth of response at 6 months and survival in patients (pts) with metastatic non-small cell lung carcinoma (mNSCLC): SPORE trial
    Moinard-Butot, F.
    Barbe-Richaud, J-B.
    Lasvergnas, J.
    Ancel, J.
    Justeau, G.
    Bender, L.
    Le Floch, H.
    Chouaid, C.
    Bylicki, O.
    Schott, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S861 - S861
  • [23] COGNITIVE CONCERNS AND PERFORMANCE IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (mNSCLC)
    Eggen, Annemarie
    Richard, Nadine
    Shen, Gerald
    Shultz, David
    Leighl, Natasha
    Liu, Geoffrey
    Sun, Alexander
    Bosma, Ingeborg
    Reyners, Anna
    Jalving, Mathilde
    Rodin, Gary
    Edelstein, Kim
    NEURO-ONCOLOGY, 2019, 21 : 159 - 159
  • [24] LKB1 Mutations in Metastatic Non-Small Cell Lung Cancer (mNSCLC): Prognostic Value in the Real World
    Golozar, A.
    Collins, J.
    Fraeman, K.
    Nordstrom, B.
    Mcewen, R.
    Shire, N.
    Higgs, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S223 - S224
  • [25] REAL-WORLD PROFILING OF NON-SMALL CELL LUNG CANCER PATIENTS IN JAPAN
    Takahashi, Chang E.
    Wakase, S.
    Ito, M.
    Taylor, T.
    VALUE IN HEALTH, 2022, 25 (01) : S121 - S122
  • [26] Health and Economic Outcomes of Pembrolizumab in the Treatment of Metastatic Non-small Cell Lung Cancer (mNSCLC) and Melanoma in Italy
    Paoletti, Martina
    Bini, Chiara
    Marcellusi, Andrea
    Mennini, Francesco Saverio
    CLINICAL DRUG INVESTIGATION, 2024, 44 (08) : 601 - 609
  • [27] Real-world analysis of biomarker testing and use of targeted therapies in metastatic non-small cell lung cancer (mNSCLC) in the United States (US)
    Dennis, Michael J.
    Abrahami, Devin
    Vieira, Maria Cecilia
    Benjumea, Darrin
    Boyd, Marley
    Shao, Anran
    Duncan, Kirsten
    Kelton, John
    Patel, Sandip P.
    CANCER RESEARCH, 2024, 84 (06)
  • [28] Real-world patterns of biomarker testing and targeted therapy in metastatic non-small cell lung cancer (mNSCLC) in the community oncology setting.
    Nadler, Eric S.
    Vasudevan, Anupama
    Davies, Kalatu
    Wang, Yunfei
    Gupta, Ravindra
    Ogale, Sarika
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Real-world economic burden of rapid disease progression (RDP) in patients (pts) with advanced/metastatic non-small cell lung cancer (aNSCLC).
    Byfield, Stacey DaCosta
    Molife, Cliff
    Batus, Marta
    Winfree, Katherine B.
    White, John C.
    Cui, Zhanglin Lin
    Lal, Lincy S.
    Stefaniak, Victoria Jennifer
    Bonomi, Philip D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer
    Peng, Tzu Rong
    Wu, Ta Wei
    AMERICAN JOURNAL OF THERAPEUTICS, 2019, 26 (04) : E537 - E538
12345